Evidence mapPaperPMID 40818936Full record

Observational studyBMC geriatrics2025

"The association of cardiometabolic diseases and related medications with cognitive performance: a cross-sectional observational study from Central Poland".

Bartłomiej K Sołtysik, Anna Cieślak-Skubel, Agnieszka Gutowska, Elisio Costa, Tomasz Kostka

Abstract readObservational Study
In one paragraph

Observational study in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bartłomiej K SołtysikDepartment of Geriatrics, Healthy Ageing Research Centre (HARC), Medical University of Lodz, Haller Sqr. No. 1, Lodz, 90-647, Poland. bartlomiej.soltysik@umed.lodz.pl.
Anna Cieślak-SkubelDepartment of Geriatrics, Healthy Ageing Research Centre (HARC), Medical University of Lodz, Haller Sqr. No. 1, Lodz, 90-647, Poland.
Agnieszka GutowskaDepartment of Geriatrics, Healthy Ageing Research Centre (HARC), Medical University of Lodz, Haller Sqr. No. 1, Lodz, 90-647, Poland.
Elisio CostaLaboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy and Porto4Ageing EIP-AHA Reference Site, UCIBIO-REQUIMTE, University of Porto, Rua de Jorge Viterbo Ferreira, 228, Porto, 4050-313, Portugal.
Tomasz KostkaDepartment of Geriatrics, Healthy Ageing Research Centre (HARC), Medical University of Lodz, Haller Sqr. No. 1, Lodz, 90-647, Poland.

Funding

Uniwersytet Medyczny w Lodzi (503/6-020-01/503-61-001; 503/6-077-01/503-61-001; 503/6-077-01/503-90-201
6 · The paper itself

Abstract

introductionGlobal ageing, the rising prevalence of cardiometabolic diseases and dementia becomes increasingly important public health topic. This relation has evoked extensive research efforts aimed at finding the link between cardiovascular health and cognitive decline. Cardiometabolic medications, widely prescribed for their beneficial effects on vascular health, are being closely examined for their potential influence on cognitive health and their capacity to modify the risk of dementia.

methodsIn this cross-sectional study, 1735 individuals from Central Poland were investigated on cardiometabolic diseases, treatments, and cognitive function. Cognitive performance was evaluated using the Mini-Mental State Examination (MMSE) dichotomized to ≥ 24 points and < 24 points.

resultsThe logistic regression revealed a strong association between age (OR:1.07, 95% CI 1.05-1.08, p < 0.001) and stroke (OR:1.43, 95% CI 1.30-1.84, p < 0.001) with worse MMSE dichotomized score. Similarly, insulin usage was linked to an increased risk of low MMSE (OR:1.33, 95%CI: 1.06-1.73, p = 0.008). In contrast, BMI (OR:0.96, 95%CI 0.94-0.98, p = 0.001), lipid disorders (OR:0.69, 95% CI 0.48-0.92, p = 0.01), use of calcium channels blockers (OR:0.71, 95% CI 0.48-0.94, p = 0.04), alpha-blockers (OR:0.54, 95% CI 0.23-0.86, p = 0.004) and angiotensin II receptor antagonists (OR 0.56, 95% CI 0.29-0.83, p = 0.001), were associated with normal cognitive functions (R

conclusionsThe results present the complex connection between cardiometabolic disorders, their treatment and cognitive functioning. The research highlights the necessity for a tailored approach in prescribing cardiovascular medications, considering their potential link with cognitive health. Especially the role of angiotensin II receptor antagonists merits further studies.

Indexed as

Cardiovascular DiseasesCognitionAgedAged, 80 and overCross-Sectional StudiesFemaleHumansMaleMiddle AgedPolandCardiometabolic medicationsCardiovascular diseaseCognitive declineDementia

Identifiers

PMID40818936
PMCPMC12357346

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.